Abbott Laboratories ABT
101.29
0.22
0.22%
as of 25 Sep
- Market cap
- $174.8B
- P/E
- 32.8×
Follow ABT
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
16.78 | 33.68 | 28.76 | 29.37 |
P/S ratio |
5.32 | 4.92 | 3.96 | 3.39 | |
P/FCF ratio |
33.73 | 29.50 | 24.25 | 20.18 | |
P/Operating CF |
83.73 | 65.80 | 136.05 | 63.48 | |
P/B ratio |
4.55 | 4.13 | 3.39 | 3.05 | |
Price to Tangible BV |
10.76 | 9.40 | 0.00 | 0.00 | |
EV/Sales |
5.44 | 5.01 | 4.56 | 3.97 | |
EV/EBITDA |
22.00 | 19.89 | 18.92 | 17.14 | |
EV/Operating CF |
26.16 | 23.22 | 21.73 | 18.67 | |
EV/FCF |
34.49 | 30.04 | 27.87 | 23.64 | |
Quick Ratio |
1.09 | 1.02 | 0.84 | 0.80 | |
Current Ratio |
1.70 | 1.58 | 1.39 | 1.38 | |
Net Debt/EBITDA |
1.83 | 1.31 | 12.45 | 9.81 | |
Debt/Assets |
15.37% | 14.91% | 30.83% | 29.86% | |
Debt/Equity |
0.25 | 0.25 | 0.65 | 0.63 | |
Asset Turnover |
0.55 | 0.53 | 0.47 | 0.48 | |
Operating CF/Net income |
1.70 | 1.87 | 1.22 | 2.68 | |
Capex/Depreciation |
(0.63) | (0.87) | (0.50) | (0.47) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
6.74% | 6.41% | 6.87% | 7.08% | |
Selling, General and Administrative Expense of Revenue |
26.84% | 27.31% | 33.50% | 31.96% | |
Intangible Assets out of Total Assets |
0.35 | 0.34 | 0.48 | 0.48 | |
Share Based Compensation of Revenue |
1.06% | 0.99% | 2.84% | 1.33% | |
Graham Net Nets |
(0.03) | (0.04) | (0.18) | (0.21) | |
Graham Number |
72.69 | 50.37 | 49.29 | 45.47 | |
Earnings Yield |
5.96% | 2.97% | 3.48% | 3.41% | |
Free Cash Flow Yield |
2.96% | 3.39% | 4.12% | 4.95% | |
Revenue per Share |
6.53 | 6.58 | 6.41 | 7.24 | |
Operating CF per Share |
1.60 | 1.90 | 0.75 | 1.43 | |
Capex per Share |
(0.28) | (0.40) | (0.23) | (0.29) | |
Free Cash Flow per Share |
1.32 | 1.51 | 0.53 | 1.14 | |
Cash per Share |
4.44 | 5.13 | 4.19 | 3.22 | |
Shareholders Equity per Share |
29.43 | 30.31 | 30.24 | 29.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.43 | 30.31 | 30.24 | 29.74 | |
Free Cash Flow |
2,291.00 | 2,626.00 | 916.00 | 1,991.00 | |
Working Capital |
10,257.00 | 9,500.00 | 7,131.00 | 6,703.00 | |
Capital Expenditures |
(496.00) | (689.00) | (399.00) | (497.00) | |
Net Current Asset Value |
(8,078.00) | (7,946.00) | (32,220.00) | (32,936.00) | |
EV/EBIT |
30.93 | 27.58 | 26.69 | 25.17 | |
Capex to Sales |
0.04 | 0.06 | 0.04 | 0.04 | |
Net Profit Margin |
14.46% | 15.50% | 9.65% | 7.37% | |
Price to Operating Income |
30.25 | 27.09 | 23.22 | 21.50 | |
| Other line items | |||||
Average Receivables |
7,594.50 | 7,427.00 | 7,768.50 | 8,285.50 | |
Average Payables |
4,078.50 | 4,217.50 | 4,446.50 | 4,550.00 | |
Average Inventory |
6,760.50 | 6,341.00 | 6,814.00 | 7,134.50 | |
Average Assets |
79,268.50 | 84,063.50 | 95,938.50 | 96,607.00 | |
Average Common Equity |
45,646.00 | 50,336.00 | 50,882.50 | 51,295.50 |
Columns are period end dates